Safety Considerations for CAR T Versus Bispecific Antibody Therapies in Relapsed/Refractory Follicular Lymphoma

Panelists discuss how both CAR T therapy and bispecific antibodies can trigger immune activation, leading to adverse effects such as fever or fatigue, but their timing and intensity differ. CAR T often produces a more acute inflammatory response soon after infusion, requiring hospitalization for monitoring. Bispecific antibodies, in contrast, are administered repeatedly and can cause milder reactions that are typically managed in outpatient settings.

Proactive safety planning minimizes risk for both treatments. Clinicians carefully screen patients, adjust dosing, and provide early intervention to prevent severe complications. Supportive medications and close coordination among specialists ensure that any adverse effects are addressed promptly, allowing patients to continue therapy safely.

These advances in safety management have expanded access to both therapeutic options. Understanding the expected adverse effects, knowing when to report symptoms, and maintaining communication with care teams help patients feel more confident throughout treatment.